Good morning, you're tuned in to Markets Desk.
HSBC's strategists are pushing back against the pessimism gripping equity markets right now, dismissing most of the concerns weighing on investor sentiment and recommending a lean into technology stocks, particularly in the United States and Asia, alongside European banks — a notable call given the macro uncertainty still hanging over rate-sensitive sectors.
Shifting to healthcare, Grail's Galleri blood test, which screens for fifty different cancers from a single draw, is facing a critical inflection point. A major clinical study fell short of proving the test could reliably detect later-stage cancers, and without that evidence, FDA approval remains uncertain — which means Medicare and private insurers are likely to keep coverage on hold, a significant commercial obstacle for Grail.
And in the financial sector, Citigroup is making a serious move into retail advertising, giving brands the ability to target ads directly to its more than seventy million customers based on their actual spending behavior. It's the latest example of banks monetizing transaction data, putting Citi in direct competition with the growing retail media networks run by JPMorgan and others.
That's the tape. Markets Desk, signing off the floor.
